PURPOSE OF REVIEW: The current overview will summarize some of the developments in the area of protein translation, including their relation to the therapeutic targeting of prostate cancer. RECENT FINDINGS: Translational control, mediated by the rate-limiting eukaryotic translation initiation factor 4E (eIF4E), drives selective translation of several oncogenic proteins, thereby contributing to tumor growth, metastasis, and treatment resistance in various cancers, including prostate cancer. As an essential regulatory hub, several oncogenic hyperactive signaling pathways appear to converge on eIF4E to promote tumorigenesis. Several approaches that target the eIF4E-dependent protein translation network are being actively studied, and it is likely that some may ultimately emerge as promising anticancer therapeutics. SUMMARY: An array of inhibitors has shown promise in targeting specific components of the translational machinery in several preclinical models of prostate cancer. It is hoped that some of these approaches may ultimately have relevance in improving the clinical outcomes of patients with advanced prostate cancer.
PURPOSE OF REVIEW: The current overview will summarize some of the developments in the area of protein translation, including their relation to the therapeutic targeting of prostate cancer. RECENT FINDINGS: Translational control, mediated by the rate-limiting eukaryotic translation initiation factor 4E (eIF4E), drives selective translation of several oncogenic proteins, thereby contributing to tumor growth, metastasis, and treatment resistance in various cancers, including prostate cancer. As an essential regulatory hub, several oncogenic hyperactive signaling pathways appear to converge on eIF4E to promote tumorigenesis. Several approaches that target the eIF4E-dependent protein translation network are being actively studied, and it is likely that some may ultimately emerge as promising anticancer therapeutics. SUMMARY: An array of inhibitors has shown promise in targeting specific components of the translational machinery in several preclinical models of prostate cancer. It is hoped that some of these approaches may ultimately have relevance in improving the clinical outcomes of patients with advanced prostate cancer.
Authors: Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke Journal: Invest New Drugs Date: 2014-04-09 Impact factor: 3.850
Authors: D Yu; C Scott; W W Jia; A De Benedetti; B J Williams; L Fazli; Y Wen; M Gleave; C Nelson; P S Rennie Journal: Cancer Gene Ther Date: 2006-01-01 Impact factor: 5.987
Authors: Ker Yu; Celine Shi; Lourdes Toral-Barza; Judy Lucas; Boris Shor; Jae Eun Kim; Wei-Guo Zhang; Robert Mahoney; Christine Gaydos; Luanna Tardio; Sung Kyoo Kim; Roger Conant; Kevin Curran; Joshua Kaplan; Jeroen Verheijen; Semiramis Ayral-Kaloustian; Tarek S Mansour; Robert T Abraham; Arie Zask; James J Gibbons Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Marie-Eve Bordeleau; Francis Robert; Baudouin Gerard; Lisa Lindqvist; Samuel M H Chen; Hans-Guido Wendel; Brigitte Brem; Harald Greger; Scott W Lowe; John A Porco; Jerry Pelletier Journal: J Clin Invest Date: 2008-07 Impact factor: 14.808
Authors: Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Vidya P Ramamurthy; Puranik Purushottamachar; Francis N Murigi; Tadas S Vasaitis; Weiliang Huang; Maureen A Kane; Yuji Zhang; Nicholas Ambulos; Sudhir Tiwari; Pratima Srivastava; Ivo P Nnane; Arif Hussain; Yun Qiu; David J Weber; Vincent C O Njar Journal: Cancers (Basel) Date: 2019-10-24 Impact factor: 6.639